… evaluate dupilumab with concomitant topical corticosteroids as treatment option in patients
with atopic dermatitis, … Dupilumab in combination with topical corticosteroids led to significant …

… dupilumab-treated patients compared with in those receiving placebo. An additional phase III
trial, CHRONOS, evaluated dupilumab treatment … % of patients treated with dupilumab, 300 …

… 1 month of dupilumab treatment was shown. EASI-50 (50% reduction of the score on Eczema
Area … 300 mg of dupilumab, and in approximately 55% of patients who received 150 mg of …

… that the epidermal abnormalities associated with atopic dermatitis might be reduced with
dupilumab treatment. We also found a substantial dupilumab-associated reduction in the level …

… Patients were evaluated three times: at initiation of dupilumab treatment and 1 and 3 months
after treatment initiation (scheduled appointments for all patients in dupilumab treatment). …

… still treated with dupilumab at 3 and 6 months was 95.6% (92.9:98.5) and 79.7% (73.2:86.8),
respectively. The reasons for stopping dupilumab treatment … with dupilumab treatment was …

… with dupilumab treatment in 95 patients with atopic dermatitis in daily … treatment before
starting dupilumab treatment or continued the immunosuppressant during dupilumab treatment, …

… Dupilumab seems to be an urgently needed milestone for patients with atopic dermatitis.
However, because prevalence of this disorder is highest in children and adolescents, the …

… Patients with moderate to severe AD who received dupilumab treatment and achieved an …
in Eczema Area and Severity Index scores (EASI-75) at week 16 in 2 previous dupilumab …

… in the dupilumab and TCS treatment groups. The rate of nonherpetic skin infections was
again reduced in this study with weekly (8%) and biweekly (11%) dupilumab treatment plus TCS …